Disposition of 2449 shares by Adam Laponis of Twist Bioscience at 38.146 subject to Rule 16b-3
| TWST Stock | USD 27.52 2.69 8.90% |
Slightly above 62% of Twist Bioscience's investor base is looking to short. The analysis of overall sentiment of trading Twist Bioscience Corp stock suggests that many investors are alarmed at this time. Twist Bioscience's investing sentiment can be driven by a variety of factors including economic data, Twist Bioscience's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Twist Bioscience Corp Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at gurufocus.com
 |
Twist Bioscience Fundamental Analysis
We analyze Twist Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Twist Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Twist Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Twist Bioscience is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Twist Bioscience Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Twist Bioscience stock to make a market-neutral strategy. Peer analysis of Twist Bioscience could also be used in its relative valuation, which is a method of valuing Twist Bioscience by comparing valuation metrics with similar companies.
Peers
Twist Bioscience Related Equities
| GH | Guardant Health | 6.69 | ||||
| PACB | Pacific Biosciences | 2.16 | ||||
| CDNA | CareDx | 1.98 | ||||
| CRL | Charles River | 0.61 | ||||
| ILMN | Illumina | 0.69 | ||||
| BEAM | Beam Therapeutics | 2.20 | ||||
| TXG | 10X Genomics | 2.70 | ||||
| IOVA | Iovance Biotherapeutics | 2.83 |
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.